Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Parkinsonism Relat Disord. 2015 Jan 5;21(3):271–276. doi: 10.1016/j.parkreldis.2014.12.027

Table 3.

CSF biomarkers at the start of Phase 2 as predictors of longitudinal cognitive change during Phase 2

Cognitive Test
SRT-Total Recall SRT-Delayed Recall New Dot Test SDMT
Cohort Biomarker coef. SE p coef. SE p coef. SE p coef. SE p
Discovery Aβ42 0.0002 0.0002 0.137 0.00004 0.00005 0.354 0.00003 0.00003 0.332 0.00007 0.0002 0.732
t-tau −0.043 0.061 0.482 −0.014 0.018 0.452 −0.017 0.012 0.135 −0.136 0.073 0.064
p-tau −0.103 0.051 0.045 −0.022 0.015 0.148 −0.008 0.010 0.415 −0.221 0.059 0.0003
p-tau/ t-tau −0.093 0.059 0.122 −0.010 0.018 0.584 0.010 0.011 0.366 −0.157 0.070 0.027
t-tau/ Aβ42 −0.070 0.058 0.231 −0.014 0.018 0.427 −0.018 0.012 0.117 −0.109 0.071 0.125
p-tau/ Aβ42 −0.106 0.046 0.023 −0.019 0.014 0.173 −0.008 0.009 0.393 −0.171 0.055 0.002
Validation Aβ42 0.00009 0.0002 0.625 −0.00003 0.00005 0.632 −0.00001 0.00003 0.887 0.0002 0.0002 0.519
t-tau −0.096 0.065 0.146 −0.020 0.018 0.277 −0.039 0.011 0.0004 −0.183 0.087 0.038
p-tau −0.141 0.059 0.019 −0.019 0.017 0.258 −0.024 0.010 0.018 −0.230 0.078 0.004
p-tau/ t-tau −0.037 0.055 0.504 0.008 0.015 0.957 0.017 0.009 0.073 −0.054 0.073 0.462
t-tau/ Aβ42 −0.127 0.069 0.068 −0.016 0.019 0.405 −0.036 0.011 0.002 −0.238 0.090 0.009
p-tau/ Aβ42 −0.108 0.050 0.031 −0.010 0.014 0.473 −0.013 0.009 0.136 −0.179 0.066 0.008
Total Aβ42 0.0002 0.0001 0.169 0.00001 0.00004 0.778 0.00001 0.00002 0.52 0.0001 0.0002 0.502
t-tau −0.071 0.045 0.116 −0.017 0.013 0.186 −0.027 0.008 0.001 −0.159 0.056 0.005
p-tau −0.122 0.038 0.002 −0.021 0.011 0.067 −0.014 0.007 0.051 −0.219 0.048 <0.0001
p-tau/ t-tau −0.061 0.040 0.131 −0.003 0.012 0.784 0.015 0.007 0.036 −0.093 0.050 0.066
t-tau/ Aβ42 −0.097 0.045 0.031 −0.014 0.013 0.261 −0.026 0.008 0.001 −0.166 0.056 0.003
p-tau/ Aβ42 −0.108 0.033 0.001 −0.014 0.010 0.146 −0.009 0.006 0.144 −0.171 0.042 <0.0001

Data shown are from mixed models with repeated measures of cognition scores as dependent variables, and sex, education, age at the beginning of Phase 2, final Phase 1 MMSE score, average UPDRS total score and average cognitive score over 6 months prior to the beginning of Phase 2, CSF biomarker at the beginning of Phase 2, follow-up time, CSF biomarker × follow-up time interaction as covariates. The intercept and the regression coefficients for the follow-up time were treated as random effects. Results for CSF biomarkers are for variable × follow-up time interaction term. Coef.: the regression coefficient, or the estimated association between the baseline biomarkers and annual change in cognitive scores; SE: standard error; SRT: Selective Reminding Test; SDMT: Symbol Digit Modalities Test; Aβ42: amyloid beta peptide 1-42; p-tau: phosphorylated tau; t-tau: total tau. Bold values indicate results that met the pre-specified criteria of having a significant p-value in both the discovery and validation cohorts.